2023-01-18 20:19 | CC:PSYB | Psybio Therapeutics Corp | 0.10 | Private Placement250 | Psybio Therapeutics 18,199,747-share private placement |
2023-01-13 18:13 | CC:PSYB | Psybio Therapeutics Corp | 0.07 | News Release200 | Psybio closes $276,689 second tranche private placement |
2023-01-10 13:00 | CC:PSYB | Psybio Therapeutics Corp | 0.08 | News Release200 | Psybio Therapeutics appoints Wisenberg as director |
2023-01-05 10:41 | CC:PSYB | Psybio Therapeutics Corp | | News Release200 | Psybio completes $633,281 1st tranche of financing |
2022-12-08 10:05 | CC:PSYB | Psybio Therapeutics Corp | 0.08 | News Release200 | Psybio files three U.S. patent applications |
2022-12-06 12:08 | CC:PSYB | Psybio Therapeutics Corp | 0.065 | News Release200 | Psybio files four U.S. PCT patent applications |
2022-12-01 12:12 | CC:PSYB | Psybio Therapeutics Corp | 0.07 | News Release200 | Psybio Therapeutics arranges $1M private placement |
2022-11-29 13:04 | CC:PSYB | Psybio Therapeutics Corp | 0.06 | News Release200 | Psybio files Q3 2022 results, talks patent filings |
2022-11-29 09:12 | CC:PSYB | Psybio Therapeutics Corp | 0.06 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2022-11-29 09:12 | CC:PSYB | Psybio Therapeutics Corp | 0.06 | SEDAR MD & A815 | SEDAR MD & A |
2022-10-11 10:30 | CC:PSYB | Psybio Therapeutics Corp | 0.125 | News Release200 | Psybio reaches agreement for psilocybin clinical trial |
2022-09-19 11:43 | CC:PSYB | Psybio Therapeutics Corp | | News Release200 | Psybio receives patent application acceptance |
2022-08-29 10:08 | CC:PSYB | Psybio Therapeutics Corp | 0.15 | SEDAR MD & A815 | SEDAR MD & A |
2022-08-29 08:51 | CC:PSYB | Psybio Therapeutics Corp | 0.15 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2022-08-11 17:02 | CC:PSYB | Psybio Therapeutics Corp | 0.085 | News Release200 | Psybio Therapeutics files data for patent conversion |
2022-08-08 12:45 | CC:PSYB | Psybio Therapeutics Corp | | News Release200 | Psybio Therapeutics applies for international patents |
2022-06-27 17:27 | CC:PSYB | Psybio Therapeutics Corp | 0.12 | News Release200 | Psybio shareholders to vote on share rollback Aug. 11 |
2022-06-02 11:56 | CC:PSYB | Psybio Therapeutics Corp | 0.07 | News Release200 | Psybio begins process development of manufacturing tech |
2022-05-30 11:20 | CC:PSYB | Psybio Therapeutics Corp | 0.07 | News Release200 | Psybio files Q1 financials; talks 2022 clinic results |
2022-05-30 07:34 | CC:PSYB | Psybio Therapeutics Corp | 0.07 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2022-05-30 07:34 | CC:PSYB | Psybio Therapeutics Corp | 0.07 | SEDAR MD & A815 | SEDAR MD & A |
2022-05-16 10:19 | CC:PSYB | Psybio Therapeutics Corp | 0.07 | News Release200 | Psybio develops purification method for compound |
2022-05-06 09:48 | CC:PSYB | Psybio Therapeutics Corp | 0.09 | News Release200 | Psybio begins blood-brain barrier permeability testing |
2022-04-27 11:35 | CC:PSYB | Psybio Therapeutics Corp | 0.10 | News Release200 | Psybio applies to convert provisional patents to full |
2022-04-13 11:46 | CC:PSYB | Psybio Therapeutics Corp | 0.09 | News Release200 | Psybio begins picking investigators for clinical trials |